Friday, January 19, 2018

Another blood test for cancer shows promise

CANCER DIGEST – Jan. 19, 2018 – A team of researchers have developed another blood test for cancer, which if confirmed in clinical trials, could identify eight cancer types from a single blood draw.

The team at Johns Hopkins University of School of Medicine published its findings in the Jan. 18, 2018 journal Science. The test, called CancerSEEK simultaneously evaluates the levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. Five of the cancers currently have no screening test.

Saturday, January 13, 2018

New test predicts age of onset of aggressive prostate cancer

CANCER DIGEST – Jan. 13, 2018 – A new test based on genomic research combined with population research is able to predict the age of onset of aggressive prostate cancer, researchers say.

The tool is based on searches of individual genomes, the entire set of genes that make up an individual, for small variations, called single-nucleotide polymorphisms or SNPs that occur more frequently in people with a particular disease compared to people without the disease.

Tuesday, December 26, 2017

Women with HPV-positive vulvar cancer have longer survival

Copyright: rocketclips / 123RF Stock Photo
CANCER DIGEST – Dec. 28, 2017 – An analysis of 18 studies of vulvar cancer involving 1,638 women showed longer survival for women who had been infected with the human papilloma virus (HPV) than women who did not have the infection, say researchers.

The study published online Nov. 16 ahead of the December 2017 issue of the International Journal of Cancer  was led by Dr. Christina Rasmussen of the Danish Cancer Society Research Center in Copenhagen, Denmark. 

Friday, December 22, 2017

New drug breaks down chemo resistance for some pancreatic tumors

Dr. Sunil Hingorani led a clinical trial of the drug PEGPH20

CANCER DIGEST – Dec. 22, 2017 – A new drug that breaks down resistance to chemo in pancreatic cancer tumors has shown promise in making progress in the the highly fatal cancer.

In a phase 2 clinical trial aimed at determining effectiveness, researchers led by Dr. Sunil Hingornai of the Fred Hutchinson Cancer Research Center in Seattle, showed the drug PEGPH20 added to treatment with a combination chemotherapy regimen of paclitaxel and gemcitabine increased overall survival by 3 months. The study was published online Dec. 12, 2017 in the Journal of Clinical Oncology.

Saturday, December 16, 2017

New drug shows promise in a variety cancers

Stock photo courtesy Wikipedia
CANCER DIGEST – Dec. 16, 2016 – A new drug that targets the protein made by a mutation of a gene common to many cancers has shown activity against a variety of tumor types, according to researchers.

The study presents the early results of a first phase clinical trial that aims to establish safe and effective doses of the drug, called ulixertinib. Such phase I clinical trials test a range of doses to determine first, whether the drug can slow or halt the progress of the cancer, and determine the side effects as well. The study results appear in Cancer Discovery, the journal of the American Association of Cancer Research.